To review the clinical background, treatment options, and outcomes for liver metastases arising from uveal melanoma, highlighting the significance of these metastases.
Key Findings:
Uveal melanoma is the most common primary intraocular malignancy in adults, with a high risk of liver metastases.
The median overall survival after detection of liver metastases is approximately 1 year, with a 2-year survival rate of only 8%.
Tebentafusp is the only systemic treatment shown to improve overall survival in metastatic uveal melanoma.
Liver-directed therapies include surgical resection, radioembolization, and isolated hepatic perfusion.
Interpretation:
Despite advancements in treatment, the prognosis for patients with liver metastases from uveal melanoma remains poor, necessitating ongoing research into effective therapies and personalized treatment approaches.
Limitations:
Limited efficacy of systemic treatments historically, including chemotherapy and immunotherapy.
Surveillance may detect smaller lesions but has not improved overall survival rates.
Conclusion:
Combining locoregional liver-directed treatments with systemic therapies may offer new avenues for improving outcomes in patients with liver metastases from uveal melanoma.
